GleamWall
中文EN

EVO Evotec SE IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1412558 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY2.0%
TTM net income YoY-133.7%
TTM EPS YoY-136.2%
Revenue 3-yr CAGR8.8%
Net income 3-yr CAGR—

Margins

Gross margin14.4%
Operating margin-17.9%
Net margin-24.6%
FCF margin-12.5%
EBITDA margin-5.1%

Returns

ROE-18.9%
ROA-9.4%
ROIC (approx.)-17.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets50.2%
Debt / equity0.00x
Current ratio1.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.09x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue14.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue796.97M781.43M
Cost of revenue682.09M606.38M
Gross profit114.88M175.05M
R&D expense50.86M68.53M
SG&A expense188.20M169.61M
Operating income-142.52M-47.51M
Pretax income-193.98M-80.59M
Income tax2.10M3.32M
Net income-196.08M-83.91M
EBITDA-40.90M45.47M
EPS (basic)-1.11-0.47
EPS (diluted)-1.11-0.47
Balance sheet
Cash & equivalents306.39M510.91M
Short-term investments90.41M93.20M
Receivables116.32M98.40M
Inventory31.12M30.89M
Current assets681.96M903.16M
PP&E, netmay include right-of-use assets (IFRS)823.94M806.56M
Goodwill282.85M275.63M
Intangibles26.44M15.45M
Total assets1.91B2.25B
Current liabilities344.58M464.57M
Short-term debt27.11M129.97M
Total liabilities959.98M1.13B
Shareholders' equity952.52M1.12B
Shares outstanding177.55M177.19M
Cash flow statement
Operating cash flow18.22M36.44M
Capital expenditure117.47M213.32M
Free cash flow-99.25M-176.88M
Investing cash flow-71.19M-13.29M
Financing cash flow-161.42M71.96M
Depreciation & amortization101.62M92.98M
Stock-based compensation5.04M9.63M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.